|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/46 | |
| A61K 38/43 | |||
| A61P 25/00 | |||
| A61K 38/48 | |||
| A61K 38/54 | |||
| A61K 38/47 | |||
| A61K 45/06 | |||
| A61K 9/00 |
| (11) | Number of the document | 3305317 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17175116.7 |
| Date of filing the European patent application | 2012-04-20 | |
| (97) | Date of publication of the European application | 2018-04-11 |
| (45) | Date of publication and mention of the grant of the patent | 2020-06-24 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201161477988 P | 2011-04-21 | US |
| (72) |
FALLON, Joan, M., US
HEIL, Matthew, US
SZIGETHY, James, F., US
FALLON, James, J., US
|
| (73) |
Curemark, LLC,
800 Westchester Avenue, Suite 528, Rye Brook, NY 10573,
US
|
| (54) | COMPOUNDS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| COMPOUNDS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS |